Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria.
Xavier Montalban, Christine Lebrun-Frénay, Jiwon Oh...
https://pubmed.ncbi.nlm.nih.gov/40975101/Actively Recruiting
Led by Central Hospital, Nancy, France · Updated on 2026-03-25
100
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the new 2024 McDonald criteria for diagnosing multiple sclerosis MS compared to the previous 2017 version. These updated criteria introduce new diagnostic elements such as additional imaging techniques, ophthalmological data, and the kappa index test in cerebrospinal fluid. The study aims to see if the 2024 criteria improve early diagnosis rates and to determine the best threshold for the kappa index test. The study involves applying both the 2017 and 2024 McDonald diagnostic criteria to patients consulting neurology departments for suspected MS between September 2025 and December 2026. Patients undergo routine diagnostic tests including brain MRIs, optic nerve imaging, ophthalmological exams, and cerebrospinal fluid analysis. The kappa index test is performed for patients seen at Nancy University Hospital, with no additional procedures beyond standard care. Follow-up assessments continue over two years to compare diagnosis rates using both criteria. Participants will be followed through their usual clinical visits and standard care procedures, with data collected from imaging reports, neurological assessments, and laboratory tests. Researchers will measure the percentage of patients diagnosed with MS at initial assessment and at intervals over two years. They will also evaluate the diagnostic value of each test and identify optimal thresholds for the kappa index. The study will help clarify which tests are most useful for timely MS diagnosis and may guide future updates to diagnostic guidelines.
CONDITIONS
Comparison of the Performance of the 2024 and 2017 McDonald Criteria for the Diagnosis of Multiple Sclerosis in Real Life
G
Guillaume Mathey, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Central Hospital, Nancy, France
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 months (initial care period)
Participants undergo neurological assessment and various diagnostic tests including brain MRI, CSF analysis, and ophthalmological consultation as part of routine care to establish a diagnosis of multiple sclerosis using both the 2017 and 2024 McDonald criteria.
1 baseline visit and up to 3 months of diagnostic assessments
Duration - Up to 2 years
Participants are followed up with clinical visits and diagnostic assessments over time to monitor progression and confirm diagnosis according to the 2017 and 2024 McDonald criteria.
Clinical and diagnostic follow-up visits at 6 months, 1 year, and 2 years
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Xavier Montalban, Christine Lebrun-Frénay, Jiwon Oh...
https://pubmed.ncbi.nlm.nih.gov/40975101/Central Hospital, Nancy, France
Lead Sponsor